PERRIGO ANNOUNCES US FDA APPROVAL FOR OMEPRAZOLE MAGNESIUM DELAYED-RELEASE MINI CAPSULES – QNT Press Release


DUBLIN, May 26, 2022 /PRNewswire/ — Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it has received final approval from the US Food and Drug Administration for Omeprazole Magnesium Delayed-Release Mini Capsules, 20 mg over-the-counter (OTC). Perrigo expects to launch Omeprazole Minis later this year.

This launch represents a first-to-market mini capsule form of omeprazole, which is indicated for treatment of frequent heartburn. This capsule is 70% smaller than the tablet version of omeprazole that is currently available, providing a differentiated and preferred product offering for consumers . The product will be marketed under retailer’s store brand labels comparable to Prilosec OTC®.

Perrigo Executive Vice President & President, Consumer Self-Care Americas, Jim Dillard commented, “This approval illustrates Perrigo’s research and development and regulatory expertise and our continued focus on product innovation to provide value for both our customers and consumers. The omeprazole mini product exemplifies our national-brand-different strategy and provides our store brand partners with a differentiated product in the marketplace.”

About Perrigo

Perrigo Company plc (NYSE; PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Led by its consumer self-care strategy, Perrigo is the largest store brand OTC player in the US in the categories in which it competes and a top 10 OTC company by revenue in Europe. Visit Perrigo online at

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center